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Long-term extension studies and observational drug registers 
have revealed an increased risk of serious infections in 
patients treated with anti-tumor necrosis factor agents, 
particularly infliximab, etanercept and adalimumab. The 
same may be true for the newer biological drugs rituximab, 
tocilizumab and abatacept, although this has yet to be 
confirmed by long-term observational studies. We review the 
risk of tuberculosis, herpes zoster and other opportunistic 
infections, and the recommendations for screening for 
tuberculosis and hepatitis B and C infections in patients with 
rheumatoid arthritis, with the aim of informing patients and 
encouraging greater awareness among physicians. 
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ABSTRACT:
KEY WORDS:
T en biological therapies for rheumatoid arthritis (RA) are currently licensed to induce disease control and/or remis-
sion and improve patients’ quality of life, but there are still 
concerns regarding the risk of serious adverse events [1,2]. A 
number of studies have shown that treatment with biological 
drugs can lead to the development of serious infections neces-
sitating hospitalization and intravenous antibiotics, and might 
even result in death [3]. 
Since anti-tumor necrosis factor (TNF) drugs were intro-
duced at the start of the century, registries have significantly 
improved our understanding of the risks associated with these 
drugs [4]. The registries contain data relating to thousands of 
patients with disabilities and co-morbidities, as well as patients 
who would be considered ineligible for randomized controlled 
trials (RCTs). Registries have consistently reported a slightly 
increased risk of severe infections (SIs), particularly lower 
respiratory tract, skin and soft tissue infections, during the first 
6 months of anti-TNF treatment in older patients, those with 
highly active disease, those taking concomitant corticosteroids, 
and those receiving monoclonal antibodies other than etaner-
cept [3-10]. They have also revealed that the time-dependent 
decrease in risk can be attributed to high risk patients discon-
tinuing anti-TNF treatment because of death, inefficacy, side 
effects, or loss to follow-up, and to improvements in functional 
status and lower corticosteroid doses [8]. 
A Cochrane Review of the anti-TNF drugs used for differ-
ent indications found that infliximab and certolizumab had the 
highest odds ratio (OR) of SIs as compared to control treat-
ments: 1.41, 95% confidence interval (CI) 0.75–2.62, and 4.75, 
95%CI 1.52–18.5 respectively [11]. Furthermore, exposure to 
more than one anti-TNF drug during therapy was shown to 
result in a twofold risk of developing an SI [12].
AnTI-TnF DRuGS
TuBERCulOSIS
Tuberculosis (TB), mainly caused by the reactivation of latent 
tuberculous foci as a result of a destabilized balance between 
host immunity and pathogen virulence [12], is the oppor-
tunistic infection most frequently associated with anti-TNF 
drugs and is highly likely to lead to widespread, complicated 
extra-pulmonary infection [13,14]. 
A recent meta-analysis of RCTs and long-term extension 
studies of RA patients found 31 cases of TB occurring during 
anti-TNF treatment (OR 1.92, 95%CI 0.91–4.03, P = 0.085). 
The incidence was higher in those treated with anti-TNF 
monoclonal antibodies (OR 307.71, 95%CI 184.79–454.93) 
than in those treated with etanercept (OR 67.58, 95%CI 12.1–
163.94), and higher in countries where TB is more frequent 
[15]. RTCs of certolizumab pegol and golimumab have shown 
significantly higher rates of TB than observed with earlier 
anti-TNF drugs, but these were conducted in countries with 
higher rates of TB [16-18]. Consequently, all candidates for 
anti-TNF drugs should be screened for TB (history, physical 
examination, purified protein derivative, chest X-ray), and it 
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is strongly recommended that those with latent TB start TB 
treatment before starting anti-TNF drugs [19], particularly in 
endemic areas. The diagnosis of latent TB is based mainly on 
the patient’s medical history and the findings on physical exam-
ination, tuberculin skin test (TST) or interferon-gamma release 
assays (IGRAs), and chest X-ray. The main disadvantages of 
TSTs (such as the need for training to interpret the results, the 
time required for the reaction, and the effect of Koch bacillus 
vaccination on the findings) [20] have been partially overcome 
by the use of IGRAs, although only limited data are available 
for some populations, such as patients recently exposed to TB, 
children aged < 5 years, and immunocompromised subjects 
(including patients with rheumatic diseases). Effective screen- 
ing and prophylaxis have decreased the risk of TB [21]. 
BACTERIAl, VIRAl AnD FunGAl InFECTIOnS
The most frequently encountered infections in anti-TNF-treated 
patients are due to bacteria and viruses, and the most frequently 
affected sites are the respiratory system, cutaneous and soft tis-
sue, and the urinary tract. According to Dixon et al. [5], there 
is a fourfold increased risk of skin and soft tissue infections in 
anti-TNF-treated patients, which suggests that TNF plays a 
greater role in host defense, particularly in the skin and soft 
tissues than in other tissue. 
Cryptococcosis, histoplasmosis and coccidioidomycosis 
have all been associated with anti-TNF drugs in endemic 
areas [22], which indicates that anti-TNF treatment should be 
started cautiously in patients living in or visiting regions with 
endemic mycoses. Patients receiving anti-TNF drugs may also 
be at increased risk of developing Pneumocystis jiroveci and 
Nocardia infection [22-24]. 
The British Society for Rheumatology Biologics Register 
(BSRBR) has shown that RA patients receiving anti-TNF 
are twice as likely to develop septic arthritis as those treated 
with non-biological disease-modifying anti-rheumatic drugs 
(DMARDs); furthermore, since this could affect the healing of 
a surgical wound [25,26], some guidelines suggest discontinuing 
biological treatment before surgery. RA flares upon discontinu-
ing treatment are more likely in patients with established disease 
than in those with early disease; therefore, TNF blockers need 
to be resumed promptly after surgery in order to avoid this risk 
[24]. Berthold et al. [27] found a higher rate of total periopera-
tive surgical site infections (SSIs) after elective orthopedic or 
hand surgery in patients continuing anti-TNF drugs, although 
this was probably related to the infrequency of this complication 
in patients who discontinued the drugs. No particular medical 
treatment (including anti-TNF drugs) was significantly associ-
ated with the risk of SSIs, but there was a trend towards a higher 
risk in patients treated with methotrexate. On the basis of their 
findings and other available evidence, the authors concluded 
that their center would continue the routine perioperative use of 
anti-TNF drugs [27]. The almost universal policy of discontinu-
ing anti-TNF drugs is therefore based on the principle of caution 
and expert opinion. 
Many reports have also suggested an increased risk of Listeria 
infection due to foods made using unpasteurized milk, or 
Salmonella infection due to undercooked eggs or meat [4], and a 
BSRBR study has shown that advising patients to avoid high risk 
foods when starting anti-TNF drugs may reduce the risk [28]. 
One of the most frequently observed adverse events in 
clinical trials is herpes zoster (HZ), a neurocutaneous disease 
characterized by a painful vescicular dermatomal rash due to 
the reactivation of varicella zoster virus (VZV); this has been 
confirmed by the German RABBIT registry [29]. A recent 
meta-analysis of seven registries found that the pooled risk 
ratio for HZ was 1.61 (95%CI 1.16–2.23, P = 0.004), and that 
severe HZ occurred in 4.9–20.9% of patients treated with anti-
TNF drugs as compared to 2.0–5.5% of those treated with 
conventional DMARDs [30]. The same meta-analysis revealed 
a significantly increased risk of HZ in up to 61% of patients with 
systemic inflammatory diseases, thus raising the question as 
to whether systematic prophylactic treatment should be given 
to those with a known history of HZ and whether previously 
unaffected patients should be vaccinated [30].
hEPATITIS B AnD C InFECTIOnS
The possible reactivation of hepatitis B virus (HBV) has been 
attributed to a relative lack of TNF or decreased T cell activa-
tion and interferon production. A number of reports indicate 
that infliximab may be associated with the reactivation of stable 
HBV infection [31], although the entity of the risk has not been 
established. HBV reactivation is related to serological status 
before initiation of anti-TNF drugs and is greater in HbsAg-
positive than in anti-HBc-positive patients [32]. A recent 
systematic review and meta-analysis of 10 studies found that 
the prevalence of HBV reactivation was 3.9% among patients 
treated with etanercept and 4.6% among those treated with 
adalimumab [33]. Furthermore, pooled prevalence among the 
patients not receiving any antiviral prophylaxis was 4.0%. The 
rate of HBV reactivation is relatively low in anti-TNF-treated 
patients with rheumatic conditions, but screening is recom-
mended with antiviral prophylaxis and early treatment with 
nucleoside/nucleotide analogues for patients with overt chronic 
HBV infection, and lamivudine prophylaxis for active and 
inactive HBV carriers [34]. Occult carriers (anti-HBc-positive, 
HbsAg-negative) requiring anti-TNF treatment do not need 
prophylaxis, but close observation is advised (HBsAg tests 
repeated every 3 months) in order to identify HBV reactivation 
and begin antiviral therapy as soon as possible [34]. Prophylaxis 
should be started at least 1 month before biotherapy and should 
be resumed (together with virological monitoring) for at least 6 
months after its discontinuation.
There are limited data on the use of anti-TNF drugs in 
chronic carriers with hepatitis C virus (HCV) infections, but 
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an SI is determined by modifiable and non-modifiable charac-
teristics such as age, co-morbidities, the use of corticosteroids, 
and functional status. Pre-treatment risk scores have been 
developed to aid treatment decision making [11]. The RABBIT 
registry findings have been validated in a more contemporary 
cohort, and an online calculator has been developed for clinical 
use [40]. However, there is still a need to increase the aware-
ness of physicians and ensure that patients are informed of the 
increased risk of infection. 
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all patients should be screened for HCV before starting anti-
TNF treatment [35]. Preliminary data suggest that the drugs are 
safe in patients with chronic hepatitis C [35], but they should 
be administered together with antiviral therapy in those with 
associated hepatitis B. 
nEWER BIOlOGICAl AGEnTS
TuBERCulOSIS, BACTERIAl AnD FunGAl InFECTIOnS
The use of the newer biological agents (abatacept, rituximab, 
tocilizumab) is associated with a high incidence of SIs: most 
of them are forms of pneumonia and pyogenic bacterial 
infections, but invasive aspergillosis and TB have occasion-
ally been reported [3,36]. 
A meta-analysis of the tocilizumab trials conducted until 
2009 did not find any increased risk of SIs in comparison with 
controls, though the risk nearly reached significance (hazard 
ratio 1.78, 95%CI 0.98–3.23) in patients receiving the higher dose 
(8 mg/kg) in combination with methotrexate [37]. Similarly, a 
meta-analysis of abatacept and rituximab (and anakinra) did 
not find that they increased the risk of SIs, but there was a non-
significant trend towards an increased risk at the higher doses 
of both rituximab (1 g vs. 500 mg) and abatacept (10 vs. 2 mg/
kg) [38]. A recent Bayesian network meta-analysis of 106 RCTs 
also found that the risk of SIs was higher at standard or high 
doses (OR 1.31 and 1.90 respectively), but not at low doses (OR 
0.93, 95%CI 0.65–1.33), and in trials lasting 6–12 months, when 
biological agents were used in combination with conventional 
DMARDs, in patients with established RA, in studies carried out 
before 2004, and in patients previously treated with conventional 
DMARDs or anti-TNF drugs [11]. 
The risk of progressive multifocal leukoencephalopathy 
associated with rituximab has received considerable attention 
since the Food and Drug Administration issued a “black box 
warning” after two cases were reported in lupus patients, 
but although case reports suggest that the risk in rituximab-
treated RA patients may be increased the absolute risk is 
extremely low [11]. 
Finally, HBV reactivation has been observed in rituximab-
treated RA patients carrying HBsAg and in those with resolved 
HBV infection, but the discontinuation of immunosuppressive 
treatment and antiviral therapy allowed the infection to be 
controlled within a few months. Consequently, prophylaxis 
with lamivudine is recommended for rituximab-treated patients 
with onco-hematologic diseases, and the watchful monitoring 
of HBsAg/HBV DNA levels is advisable for all the other 
indications [39]. 
COnCluSIOnS
SIs are major adverse events associated with the use of biologi-
cal agents but are also reported in patients treated with metho-
trexate, the anchor drug for treating RA. The risk of developing 
Original articles
 167
IMAJ • VOL 18 • march-aPrIL 2016
with inflammatory rheumatic disease. An observational study on surgical site 
infections in 1,596 elective orthopedic and hand surgery procedures. Acta 
Orthop 2013; 84: 495-501. 
28. Davies R, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, 
Symmons DP, Hyrich KL; on behalf of the BSRBR. Influence of anti-TNF 
patient warning regarding avoidance of high risk foods on rates of listeria and 
salmonella infections in the UK. Ann Rheum Dis 2013; 72 (3): 461-2.
29. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid 
arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12. 
30. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-
tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic 
review and meta-analysis. Joint Bone Spine 2014; 81: 215-21.
31. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant 
hepatitis B virus related chronic hepatitis during infliximab treatment for severe 
spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-9.
32. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. BIOGEAS Study 
Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis 
factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 
90: 359-71. 
33. Cantini F, Boccia S, Goletti D, et al. HBV reactivation in patients treated with 
antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic 
conditions: a systematic review and meta-analysis. Int J Rheumatol 2014; 2014: 
926836.
34. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF 
drugs in patients with hepatitis B or C virus infection: safety and clinical 
management. Expert Opin Biol Ther 2012; 12: 193-207.
35. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid 
arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 
51: 800-4.
36. Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-
term safety of abatacept in patients with rheumatoid arthritis. Autoimmun 
Rev 2013; 12: 1115-17.
37. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including 
serious infections in rheumatoid arthritis patients treated with tocilizumab: 
a systematic literature review and meta-analysis of randomized controlled 
trials. Rheumatology (Oxford) 2011; 50: 552-62. 
38. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, 
abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of 
randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
39. Viganò M1, Mangia G, Lampertico P. Management of patients with overt 
or resolved hepatitis B virus infection undergoing rituximab therapy. Expert 
Opin Biol Ther 2014; 14: 1019-31. 
40. RABBIT Risk Score of Infections. 2014 November 3. Available from: http://
www.biologika-register.de/en/home/risk- score.
15. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis 
in patients with chronic immune-mediated inflammatory diseases treated with 
biologics and tofacitinib: a systematic review and meta-analysis of randomized 
controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 
53 (10): 1872-85.
16. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-
tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every 
four weeks in methotrexate-naive patients with active rheumatoid arthritis: 
twenty-four-week results of a phase III, multicenter, randomized, double-blind, 
placebo-controlled study of golimumab before methotrexate as first-line therapy 
for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83. 
17. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab 
pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year 
results from the RAPID 1 trial. Rheumatology (Oxford) 2012; 51: 1628-38. 
18. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab 
pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A 
randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
19. Cantini F, Nannini C, Niccoli L, et al., SAFEBIO (Italian multidisciplinary task 
force for screening of tuberculosis before and during biologic therapy). Guidance 
for the management of patients with latent tuberculosis infection requiring 
biologic therapy in rheumatology and dermatology clinical practice. Autoimmun 
Rev 2015; 14: 503-9.
20. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated 
guidelines for using interferon gamma release assays to detect Mycobacterium 
tuberculosis infection – United States. MMWR 2010; 59 (RR-5): 1-25.
21. Arkema EV, Jonsson J, Baecklund E, et al. Are patients with rheumatoid arthritis 
still at an increased risk of tuberculosis and what is the role of biological 
treatments? Ann Rheum Dis 2015; 74 (6): 1212-17.
22. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections 
complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc 2008; 
83: 181-9.
23. Alvarez B, Arcos J, Fernández-Guerrero ML. Pulmonary infectious diseases 
in patients with primary immunodeficiency and those treated with biologic 
immunomodulating agents. Curr Opin Pulm Med 2011; 17: 172-9. 
24. Zisman D, Haddad A, Hashoul S, et al. Hospitalizations of patients treated with 
anti-tumor necrosis factor-α agents – a retrospective cohort analysis. J Rheumatol 
2013; 40: 16-22. 
25. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with 
rheumatoid arthritis and the effect of anti-TNF therapy: results from the British 
Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-14. 
26. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be 
discontinued in rheumatoid arthritis patients undergoing elective orthopaedic 
surgery? A systematic review of the evidence. Rheumatol Int 2012; 32: 5-13. 
27. Berthold E, Geborek P, Gülfe A. Continuation of TNF blockade in patients 
Classical human leukocyte antigen (HLA) genes confer the 
strongest, but not the only, genetic susceptibility to type 1 
diabetes. Killer cell immunoglobulin-like receptors (KIR), on 
natural killer (NK) cells, bind ligands including class I HLA. 
Traherne et al. examined the presence or absence, with copy 
number, of KIR loci in 1698 individuals, from 339 multiplex 
type 1 diabetes families, from the Human Biological Data 
Interchange, previously genotyped for HLA. Combining family 
data with KIR copy number information allowed assignment of 
haplotypes using identity by descent. This is the first disease 
study to use KIR copy number typing and unambiguously 
define haplotypes by gene transmission. KIR A1 haplotypes 
were positively associated with T1D in the subset of patients 
without the high T1D risk HLA genotype, DR3/DR4 (odds 
ratio 1.29, P = 0.0096). The data point to a role for KIR in 
type 1 diabetes risk in late-onset patients. In the top quartile 
(age of onset > 14), KIR A2 haplotype was overtransmitted 
(63.4%, odds ratio 1.73, P = 0.024) and KIR B haplotypes 
were undertransmitted (41.1%, odds ratio 0.70, P = 0.0052) 
to patients. The data suggest that inhibitory ‘A’ haplotypes are 
predisposing and stimulatory ‘B’ haplotypes confer protection 
in both DR3/DR4-negative and late-onset patient groups. 
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Eitan Israeli 
Capsule
KIR haplotypes are associated with late-onset type 1 diabetes in European-American families
